FRM
EIGR

Fox Run Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Fox Run Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-412
Closed -$93K – 945
2022
Q3 		$93K Buy
+412
New +$101K 0.04% 554

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Fox Run Management's EIGR Position: Q4 2022 in Review

Fox Run Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 412 shares — an estimated $93K sold.

Fox Run Management first reported a position in EIGR in Q3 2022 and held it in 1 quarter. The position peaked at $93K in Q3 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Fox Run Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Fox Run Management sold 412 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $93K.
  • Fox Run Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Fox Run Management's Eiger BioPharmaceuticals, Inc. position peaked at $93K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Fox Run Management's 13F filing for Q4 2022, filed 7 Feb 2023.